Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6056)
All Articles published online
|
Sep 15, 2012 (publication date) through May 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Blüher M, Kurz I, Dannenmaier S, Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes 2012; 3(9): 161-169 [PMID: 23125906 DOI: 10.4239/wjd.v3.i9.161] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v3/i9/161.htm |
| Number | Citing Articles |
| 1 |
Salah Shelbaya, Sameh Rakha. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. Current Medical Research and Opinion 2017; 33(5): 797 doi: 10.1080/03007995.2016.1277199
|
| 2 |
Matthias Blüher, Ira Kurz, Simone Dannenmaier, Markus Dworak. Pill Burden in Patients With Type 2 Diabetes in Germany: Subanalysis From the Prospective, Noninterventional PROVIL Study. Clinical Diabetes 2015; 33(2): 55 doi: 10.2337/diaclin.33.2.55
|
| 3 |
Sosale R. Aravind. Adding a DPP-4 inhibitor to metformin therapy may be safer than you think. Current Medical Research and Opinion 2014; 30(5): 791 doi: 10.1185/03007995.2014.893867
|
| 4 |
Iu Sh Khalimov. DPP-4 inhibitors and hypoglycemia in the patients with type 2 diabetes mellitus. Problems of Endocrinology 2013; 59(5): 72 doi: 10.14341/probl201359572-80
|
| 5 |
André J. Scheen. Careful use to minimize adverse events of oral antidiabetic medications in the elderly. Expert Opinion on Pharmacotherapy 2021; 22(16): 2149 doi: 10.1080/14656566.2021.1912735
|
| 6 |
João Jácome de Castro, Mafalda Marcelino, João Miguel Fernandes, Chantal Mathieu, Giovanni Bader. Efetividade e segurança de vildagliptina comparativamente com outros antidiabéticos orais em doentes com diabetes tipo 2: estudo EDGE em Portugal. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo 2016; 11(1): 34 doi: 10.1016/j.rpedm.2015.06.001
|
| 7 |
Rüdiger Göke, Giovanni Bader, Markus Dworak. Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany. Diabetes Therapy 2014; 5(1): 183 doi: 10.1007/s13300-014-0060-4
|
| 8 |
Goksun Ayvaz, Lezzan Keskin, Fulya Akin, Hatice Sebile Dokmetas, Ertugrul Tasan, Idilhan Baloglu Ar, Emel Uren. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey – GALATA study. Current Medical Research and Opinion 2015; 31(4): 623 doi: 10.1185/03007995.2015.1019609
|
| 9 |
GR Sridhar, Kaushik Pandit, Sona Warrier, Ashish Birla. Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review. Cureus 2023; doi: 10.7759/cureus.39204
|
| 10 |
R. Rosales, E. Abou Jaoude, M. Al‐Arouj, A. Fawwad, A. Orabi, P. Shah, S. DiTommaso, J. Vaz, Z. A. Latif. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study. Diabetes, Obesity and Metabolism 2015; 17(6): 603 doi: 10.1111/dom.12436
|
| 11 |
Suetonia C. Palmer, Marinella Ruospo, Germaine Wong, Jonathan C. Craig, Massimo Petruzzi, Michele De Benedittis, Pauline Ford, David W. Johnson, Marcello Tonelli, Patrizia Natale, Valeria Saglimbene, Fabio Pellegrini, Eduardo Celia, Ruben Gelfman, Miguel R. Leal, Marietta Torok, Paul Stroumza, Luc Frantzen, Anna Bednarek-Skublewska, Jan Dulawa, Domingo del Castillo, Amparo G. Bernat, Jorgen Hegbrant, Charlotta Wollheim, Staffan Schon, Letizia Gargano, Casper P. Bots, Giovanni F.M. Strippoli. Patterns of oral disease in adults with chronic kidney disease treated with hemodialysis. Nephrology Dialysis Transplantation 2016; 31(10): 1647 doi: 10.1093/ndt/gfv413
|
| 12 |
André J. Scheen. Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes & Metabolism 2021; 47(6): 101275 doi: 10.1016/j.diabet.2021.101275
|
| 13 |
Gillian M. Keating. Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 2014; 74(5): 587 doi: 10.1007/s40265-014-0199-3
|
| 14 |
André J Scheen. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 2015; 14(4): 505 doi: 10.1517/14740338.2015.1006625
|
| 15 |
Christine Berndt-Zipfel, Georg Michelson, Markus Dworak, Michael Mitry, Andrea Löffler, Andreas Pfützner, Thomas Forst. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus – results from an exploratory study. Cardiovascular Diabetology 2013; 12(1) doi: 10.1186/1475-2840-12-59
|
| 16 |
Mousa Al Omari, Yousef Khader, Ali Shakir Dauod, Othman Ahmed Beni Yonis, Adi Harbi Mohammad Khassawneh. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin. Journal of Drug Assessment 2016; 5(1): 29 doi: 10.1080/21556660.2016.1252379
|
| 17 |
Luc Van Gaal, Michel P. Hermans, Evis Daci, Kris Denhaerynck, Lut De Meester, Karen MacDonald, Ivo Abraham, Stefaan Vancayzeele, Michael Maris. Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study. Diabetes Therapy 2019; 10(3): 965 doi: 10.1007/s13300-019-0601-y
|